3-43081361-C-T
Variant summary
Our verdict is Likely benign. Variant got -3 ACMG points: 2P and 5B. PM2BP4_StrongBS1_Supporting
The NM_032806.6(POMGNT2):c.71G>A(p.Arg24Gln) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000436 in 1,608,896 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_032806.6 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -3 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
POMGNT2 | NM_032806.6 | c.71G>A | p.Arg24Gln | missense_variant | 2/2 | ENST00000344697.3 | NP_116195.2 | |
POMGNT2 | XM_005265515.4 | c.71G>A | p.Arg24Gln | missense_variant | 3/3 | XP_005265572.1 | ||
POMGNT2 | XM_011534163.3 | c.71G>A | p.Arg24Gln | missense_variant | 3/3 | XP_011532465.1 | ||
POMGNT2 | XM_017007353.2 | c.71G>A | p.Arg24Gln | missense_variant | 4/4 | XP_016862842.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
POMGNT2 | ENST00000344697.3 | c.71G>A | p.Arg24Gln | missense_variant | 2/2 | 1 | NM_032806.6 | ENSP00000344125 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000427 AC: 65AN: 152166Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.000338 AC: 82AN: 242922Hom.: 0 AF XY: 0.000242 AC XY: 32AN XY: 132366
GnomAD4 exome AF: 0.000437 AC: 637AN: 1456612Hom.: 0 Cov.: 37 AF XY: 0.000407 AC XY: 295AN XY: 724740
GnomAD4 genome AF: 0.000427 AC: 65AN: 152284Hom.: 0 Cov.: 33 AF XY: 0.000403 AC XY: 30AN XY: 74452
ClinVar
Submissions by phenotype
not provided Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Athena Diagnostics | Nov 03, 2021 | This observation is not an independent occurrence and has been identified in the same individual by RCIGM, the other laboratory participating in the GEMINI study. - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jun 26, 2023 | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Jul 27, 2016 | - - |
POMGNT2-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jul 11, 2024 | The POMGNT2 c.71G>A variant is predicted to result in the amino acid substitution p.Arg24Gln. This variant has been reported in the homozygous state in an acutely ill infant (eTable 2 in Maron et al 2023. PubMed ID: 37432431). This variant is reported in 0.071% of alleles in individuals of Latino descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 13, 2023 | The c.71G>A (p.R24Q) alteration is located in exon 2 (coding exon 1) of the POMGNT2 gene. This alteration results from a G to A substitution at nucleotide position 71, causing the arginine (R) at amino acid position 24 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 8 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 23, 2022 | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 24 of the POMGNT2 protein (p.Arg24Gln). This variant is present in population databases (rs139245562, gnomAD 0.08%). This variant has not been reported in the literature in individuals affected with POMGNT2-related conditions. ClinVar contains an entry for this variant (Variation ID: 436370). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at